quinoline-4-carbonyl chloride hydrochloride | 91799-73-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: quinoline-4-carbonyl chloride hydrochloride
• 英文别名: quinoline-4-carboxylic acid chloride hydrochloride；quinoline-4-carbonyl chloride;hydrochloride
• CAS: 91799-73-4
• 化学式: C₁₀H₆ClNO*ClH
• 分子量: 228.078
• InChiKey: WIDRCMOETAIOQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.04
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  quinoline-4-carbonyl chloride hydrochloride 在 劳森试剂 、 sodium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 反应 32.0h， 生成 N-<(4-quinolinyl)thiocarbonyl>-N-methylglycine
  参考文献：
  名称：

  Synthesis and aldose reductase inhibitory activity of N-(quinolinyl thiocarbonyl) glycine derivatives

  摘要：

  The onset of diabetic complications may be prevented by the inhibition of aldose reductase. Derivatives of N-(quinolinyl thiocarbonyl) glycine were prepared and their in vitro and ex vivo aldose reductase inhibitory activities were tested on rat lens. The cincophen derivatives were the most potent in vitro with an enzyme inhibition value of 29% at 10(-8) M and 91% at 10(-7) M for the N-[(2-phenylquinolin-4-yl)thiocarbonyl]-N-methylglycine compound 10a This activity was shown to be dependent on the nature of the substituents and seems to be optimal for the acids; esters were found to be inactive. No compound have shown ex vivo inhibitory activity. It is concluded that the lack of ex vivo activity is likely due to a poor bioavailability or a bad penetration of the compounds in target tissue (lens).

  DOI：

  10.1016/0223-5234(92)90032-v
• 作为产物：
  描述：

  喹啉-4-羧酸 在 氯化亚砜 作用下， 反应 1.5h， 生成 quinoline-4-carbonyl chloride hydrochloride
  参考文献：
  名称：

  (-)-Aristoquinoline 通过分子内腈离子环化的全合成

  摘要：

  生物碱马里多喹啉的对映选择性全合成已通过七个步骤实现，总产率为 26%。为了避免化学计量的汞试剂或含叠氮化物的中间体，还开发了一种有用的合成结构单元 (-)-α-萜品基胺的新制备方法。优化合成路线的关键步骤包括分子内腈离子环化以形成特征氮杂双环 [3.3.1] 壬烷环系统和所得亚胺混合物的非对映选择性还原以提供天然产物。还获得了一种含有环外烯烃的马兜铃喹啉异构体，并发现其表现出不寻常的色谱和光谱特性。

  DOI：

  10.1055/s-0041-1737276

文献信息

• Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)
  作者：Koen Jansen、Leen Heirbaut、Robert Verkerk、Jonathan D. Cheng、Jurgen Joossens、Paul Cos、Louis Maes、Anne-Marie Lambeir、Ingrid De Meester、Koen Augustyns、Pieter Van der Veken

  DOI：10.1021/jm500031w

  日期：2014.4.10

  (2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors. In the present study, we explore in detail the structure–activity relationship around this core scaffold. We report extensively optimized compounds that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP)

  成纤维细胞活化蛋白（FAP）是一种与二肽基肽酶IV（DPPIV）相关的丝氨酸蛋白酶。它已令人信服地与涉及细胞外基质重塑的多种疾病状态联系在一起。FAP抑制已被研究作为这些疾病中的几种的治疗选择，迄今为止，大多数注意力都集中在肿瘤学应用上。我们之前发现了N -4-喹啉基-Gly-（2 S）-cyanoPro支架可能是高效和选择性FAP抑制剂的一种可能。在本研究中，我们将详细探讨围绕该核心支架的结构与活性之间的关系。我们报告了广泛优化的化合物，这些化合物对相关的二肽基肽酶（DPPs）DPPIV，DPP9，DPPII和脯氨酰寡肽酶（PREP）表现出低纳摩尔抑制力和高选择性。发现所选化合物的log  D值，血浆稳定性和微粒体稳定性非常令人满意。选定抑制剂在小鼠体内的药代动力学评估表明，其口服生物利用度高，血浆半衰期高，并且具有体内选择性和完全抑制FAP的潜力。
• [EN] NOVEL FAP INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE FAP
  申请人：UNIV ANTWERPEN

  公开号：WO2013107820A1

  公开（公告）日：2013-07-25

  The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

  本发明涉及对FAP（成纤维细胞活化蛋白）具有高选择性和特异性的新型抑制剂。所述抑制剂可用作人类和/或兽药，特别是用于治疗和/或预防FAP相关疾病，如但不限于增殖性疾病。
• 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and
  申请人：Sterling Winthrop Inc.

  公开号：US05294612A1

  公开（公告）日：1994-03-15

  Novel 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-ones, useful in treating cardiovascular disease, are prepared by reacting a 5-amino-1H-pyrazole-4-carboxamide with heterocyclylcarboxaldehyde or by reacting a 5-amino-1H-pyrazole-4-carbonitrile with a heterocyclylcarboxamidine, followed by diazotization and hydrolysis of the resulting 4-amino-6-heterocyclyl-pyrazolo[3,4-d]pyrimidine.

  新型6-杂环基嘧啶并[3,4-d]嘧啶-4-酮，用于治疗心血管疾病，通过将5-氨基-1H-嘧啶-4-甲酰胺与杂环基羰基或将5-氨基-1H-嘧啶-4-碳腈与杂环基羧酰胺反应制备，随后对所得的4-氨基-6-杂环基嘧啶并[3,4-d]嘧啶进行重氮化和水解。
• NOVEL FAP INHIBITORS
  申请人：UNIVERSITEIT ANTWERPEN

  公开号：US20140357650A1

  公开（公告）日：2014-12-04

  The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

  本发明涉及具有高选择性和特异性的新型抑制剂，用于FAP（成纤维细胞激活蛋白）。所述抑制剂可用作人类和/或兽医药物，特别用于治疗和/或预防与FAP相关的疾病，如但不限于增殖性疾病。
• Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors
  申请人：Gobbi Luca

  公开号：US20070197531A1

  公开（公告）日：2007-08-23

  The present invention relates to compounds of the general formula as dual modulators of the 5-HT 2a and D 3 receptors useful against CNS disorders, wherein A, R 1 , R 2 , n, p, q and r are as defined in the specification.

  本发明涉及一般公式的化合物，作为5-HT2a和D3受体的双重调节剂，用于对抗中枢神经系统疾病，其中A、R1、R2、n、p、q和r的定义如规范中所述。